summit trial tirzepatide results Reaching the SUMMIT? Benefits and potential risks associated with the use of in heart failure with preserved ejection fraction SURMOUNT-1 Trial 📌 Most viewed this week

Verdict at a Glance CagriSema demonstrates meaningfully greater weight loss than semaglutide alone (20.4% vs 14.9%), driven by the complementary amylin pathway from cagrilintide

Timeline and Availability Retatrutide is currently in Phase 3 trials (as of 2025)

This proactive timeline reduces stress and unplanned exposure risk

However, their absorption rate can be quite low, ranging from 15-25%

The introduction of these pharmacological interventions represents a paradigm shift, acknowledging the biological factors that contribute to obesity and making safe, effective weight loss more attainable

Semaglutide is a long-acting GLP-1 receptor agonist with structural homology to native human GLP-1